| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/02/2006 | WO2006021814A2 Medicament |
| 03/02/2006 | WO2006021451A2 Methods and compounds for treating diabetes |
| 03/02/2006 | WO2006021409A1 Alpha-keto carbonyl calpain inhibitors |
| 03/02/2006 | WO2006021374A1 Treatment of transformed or infected biological cells |
| 03/02/2006 | WO2006001499A3 Metastin derivatives and use thereof |
| 03/02/2006 | WO2006000448A3 Fc-INTERFERON-BETA FUSION PROTEINS |
| 03/02/2006 | WO2005121172A3 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation |
| 03/02/2006 | WO2005118886A3 Stable peptide mimetic of hiv gp41 fusion intermediate |
| 03/02/2006 | WO2005117979A3 Use of il-17 in the treatment of fertility-related disorders |
| 03/02/2006 | WO2005116051A3 Tumor-associated peptides that bind to mhc-molecules |
| 03/02/2006 | WO2005115517A3 Methods of treating diabetes |
| 03/02/2006 | WO2005113590A3 Bmp10 propeptides and related methods |
| 03/02/2006 | WO2005105136A9 Nanogene therapy for cell proliferation disorders |
| 03/02/2006 | WO2005105133A3 Methods and compositions for preserving the viability of photoreceptor cells |
| 03/02/2006 | WO2005100990A3 Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2) |
| 03/02/2006 | WO2005092114A3 Compositions and methods for destruction of prion infectious proteins |
| 03/02/2006 | WO2005084714A3 Raav-neprilysin compositions and methods of use |
| 03/02/2006 | WO2005077056A3 Methods and compositions for the treatment of inflammation |
| 03/02/2006 | WO2005069009A3 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN STEROID PROGESTIN RECEPTOR BETA (mSR-BETA) |
| 03/02/2006 | WO2005051331A3 Chaperone-based therapy for niemann-pick disease |
| 03/02/2006 | WO2005045038A3 RNA interference mediated inhibition of GPRA and AAA1 gene expression using short nucleic acid (siNA) |
| 03/02/2006 | WO2005045032A3 RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 03/02/2006 | WO2005044845A3 Protein binding miniature proteins |
| 03/02/2006 | WO2005040379A3 RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 03/02/2006 | WO2005019429A3 Compositions and methods for enhancing phagocytosis or phagocyte activity |
| 03/02/2006 | WO2005012513A8 Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regenaration |
| 03/02/2006 | WO2005000351A3 Combination therapy for b cell disorders |
| 03/02/2006 | WO2004094465A3 Synthetic molecules that mimic chemokines |
| 03/02/2006 | WO2004069169A3 Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same |
| 03/02/2006 | WO2004046331A3 2’-branched nucleosides and flaviviridae mutation |
| 03/02/2006 | WO2004042014A3 Mono- and diacylglycerol acyltransferases and methods of use thereof |
| 03/02/2006 | WO2004039334A3 CALCIUM-SENSING RECEPTOR 2 (CaR2) AND METHODS FOR USING |
| 03/02/2006 | WO2004029631A3 Method for identifying bhs-specific proteins and fragments thereof |
| 03/02/2006 | WO2004020583A3 Polynucleotide predictor set for identifying protein tyrosine kinase modulators |
| 03/02/2006 | WO2003090686A3 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| 03/02/2006 | WO2003039232A3 Endothelial cell derived hemotopoietic growth factor |
| 03/02/2006 | WO2003031464A3 Remodeling and glycoconjugation of peptides |
| 03/02/2006 | WO2002072769A3 Human serpin polypeptides |
| 03/02/2006 | US20060047107 Cortistatin: neuropeptides, compositions and methods |
| 03/02/2006 | US20060046979 Organic compounds |
| 03/02/2006 | US20060046967 Prodrugs containing novel bio-cleavable linkers |
| 03/02/2006 | US20060046966 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 03/02/2006 | US20060046965 racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides |
| 03/02/2006 | US20060046964 Pharmaceutical formulations and methods |
| 03/02/2006 | US20060046963 Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNs) in a tissue, its selection, pharmaceutical compositions and use |
| 03/02/2006 | US20060046962 Absorption enhancers for drug administration |
| 03/02/2006 | US20060046961 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/02/2006 | US20060046960 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/02/2006 | US20060046959 Novel leptin antagonist |
| 03/02/2006 | US20060046958 Side effect reduction |
| 03/02/2006 | US20060046957 Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| 03/02/2006 | US20060046956 Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease |
| 03/02/2006 | US20060046283 DNA encoding anti-apoptotic protein and recombinant 30K protein |
| 03/02/2006 | US20060046271 Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides |
| 03/02/2006 | US20060046255 Use of nucleic acid analogues in diagnostics and analytical procedures |
| 03/02/2006 | US20060046250 Novel use of aim 3 acting as a tumor suppressor |
| 03/02/2006 | US20060045930 Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders |
| 03/02/2006 | US20060045920 animal extracts comprising protein hydrozylates, hydrolyzed type II collagen, used for inducing cartilage formation, prohylaxis of connective tissue disorders and replenishing skin viscoelasticity; wound healing agents |
| 03/02/2006 | US20060045904 Joint therapy |
| 03/02/2006 | US20060045896 Inhibiting the formation of advanced glycation endproducts (AGEs) in the skin;aging resistance; wrinkle resistance; oxidation resistance; cosmetics; along withCarnosine, Astaxanthin, Tocotrienol, Tocopherol, grape proanthocyanidin, and ethylenediamine tetracetic acid |
| 03/02/2006 | US20060045883 Anti-cancer vaccines |
| 03/02/2006 | US20060045880 Methods for modulating angiogenesis and apoptosis with apelin compositions |
| 03/02/2006 | US20060045878 Pancreas-derived plasminogen activator inhibitor |
| 03/02/2006 | US20060045875 Method of use of crotoxin as an anti-retroviral agent |
| 03/02/2006 | US20060045874 Such as Hurler syndrome and Batten by administering an aminoglycosidesuch as gentamicin, G418, hygromycin B, paromomycin, tobramycin, lividomycin A, amikacin, sisomycin, or neomycin in combination with an enzyme effective for enzyme replacement therapy, a polyionic compound or gene therapy |
| 03/02/2006 | US20060045869 Absorption enhancers for drug administration |
| 03/02/2006 | US20060045868 Absorption enhancers for drug administration |
| 03/02/2006 | US20060045867 Regeneration method for treating heart diseases and vascular system diseases using medicament |
| 03/02/2006 | US20060045853 Using tissue plasminogen activator finger domain specific immunolglobulins as tool in diagnosis of diabbetes and/or alzheimer's disease |
| 03/02/2006 | DE102004042894A1 Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen Use of blockers of the NKG2D receptor / NKG2D-ligand interaction in autoimmune diseases |
| 03/02/2006 | CA2578201A1 Formulations and methods for modulating satiety |
| 03/02/2006 | CA2577987A1 Alpha-keto carbonyl calpain inhibitors |
| 03/02/2006 | CA2577755A1 Neublastin variants |
| 03/02/2006 | CA2577711A1 Microprojection array patch for transdermal delivery of vascular endothelial growth factors |
| 03/02/2006 | CA2577690A1 Refolding transforming growth factor beta family proteins |
| 03/02/2006 | CA2577631A1 Methods and compositions for treating allergic inflammation |
| 03/02/2006 | CA2577326A1 Selective vpac2 receptor peptide agonists |
| 03/02/2006 | CA2577196A1 Peptide inhibitors for mediating stress responses |
| 03/02/2006 | CA2577156A1 Guanylhydrazone compounds, compositions, methods of making and using |
| 03/02/2006 | CA2577010A1 Selective vpac2 receptor peptide agonists |
| 03/02/2006 | CA2576915A1 Growth-hormone secretagogues |
| 03/02/2006 | CA2576755A1 Selective vpac2 receptor peptide agonists |
| 03/02/2006 | CA2576473A1 Liquid preparation of physiologically active peptide |
| 03/02/2006 | CA2576247A1 Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, in staphylococcus aureus |
| 03/02/2006 | CA2576217A1 Selective vpac2 receptor peptide agonists |
| 03/02/2006 | CA2576015A1 Method of treating, preventing, inhibiting or reducing damage to cardiac tissue |
| 03/02/2006 | CA2572777A1 Medicament comprising corticotropin releasing factor and proopiomelanocortin, and uses thereof |
| 03/01/2006 | EP1630230A2 Streptococcus pneumoniae proteins and nucleic acids |
| 03/01/2006 | EP1630229A2 Melanoma antigens |
| 03/01/2006 | EP1629851A1 Remedy for diabetes |
| 03/01/2006 | EP1629849A2 Pharmaceutical compositions comprising exendins and agonists thereof |
| 03/01/2006 | EP1629848A1 Apoptosis inducing agent and method of inducing apoptosis |
| 03/01/2006 | EP1629832A1 A pharmaceutical formulation comprising human growth hormone, an amino acid and a non-ionic detergent |
| 03/01/2006 | EP1629284A2 Methods for identifying modulators of kinesin activity |
| 03/01/2006 | EP1629283A2 Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
| 03/01/2006 | EP1629106A2 METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS |
| 03/01/2006 | EP1629099A1 Compositions and methods for preventing and treating liver cirrhosis |
| 03/01/2006 | EP1629098A2 Complement inhibitors from ticks |
| 03/01/2006 | EP1629085A2 Transfection agents |
| 03/01/2006 | EP1629008A1 Tnf-like secreted protein |